BRTX — BioRestorative Therapies Inc
NASDAQ · Healthcare · Biotechnology
$0.20
+$0.00 (+2.14%)
BioRestorative Therapies Inc (BRTX) is a biotechnology company listed on NASDAQ. It is led by Lance Alstodt, based in 40 Marcus Drive, Melville, NY, United States, 11747, with about 13 employees. BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Latest reported BRTX revenue for 2025-09-30 was $11.8K. Net income was -$3.0M. Revenue was down 96.1% from 2025-06-30 to 2025-09-30. BRTX currently screens at market cap $10.2M.
On the latest cached filing, BRTX: AND EXCHANGE COMMISSION (8-K 2026-09-01). This BRTX stock page is the analysis view: what changed in the numbers, and why it matters for BioRestorative Therapies Inc.
Use this BRTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BRTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BRTX SEC filings page. Lician reads the product cache first so this HTML stays unique to BioRestorative Therapies Inc even when a live quote feed is slow.
What changed in BRTX
8-K · 2026-09-01
BRTX: AND EXCHANGE COMMISSION
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
BRTX Key Statistics
Market Cap
$10.18M
Volume
58,821
Previous Close
$0.22
Day Range
$0.21 – $0.22
P/B Ratio
2.96
EPS
-$1.16
Revenue
$401.00K
Net Income
-$8.98M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+175.0%
Profit Margin
-2239.2%
Employees
13
BRTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $401.00K | $145.80K | $119.80K | $46.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$8.98M | -$10.42M | -$18.49M | -$44.30M |
| EPS (Diluted) | -$1.16 | -$2.47 | -$5.11 | $0.00 |
Total Assets
$12.28M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$547.89K
Operating Cash Flow
-$8.23M
Free Cash Flow
$0.00
BioRestorative Therapies Inc Company Information
- Chairman of the Board, President & CEO
- Lance Alstodt
- Headquarters
- 40 Marcus Drive, Melville, NY, United States, 11747
- Website
- www.biorestorative.com
- Phone
- 631 760 8100
- IPO / Founded
- 2007-07-27
- Sector
- Healthcare
- Industry
- Biotechnology